This page tracks investment trends, pipeline developments, and commercial opportunities in antibody therapeutics for neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).
| Company | Focus Areas | Notable Programs | Market Cap (2026) |
|---|---|---|---|
| Biogen | AD, PD | Lecanemab[1], Aducanumab | $25B |
| Roche | AD | Gantenerumab[2], Crenezumab | $280B |
| Eli Lilly | AD | Donanemab[3], Solanezumab | $320B |
| Johnson & Johnson | AD, PD | Tau antibodies (Phase II) | $400B |
| AbbVie | AD | ABBV-916 (anti-Aβ protofibril) | $250B |
| Prothelia | ALS, FTD | ALZ-101 (anti-tau) | $500M |
| Drug | Company | Phase | Target | Indication | Status |
|---|---|---|---|---|---|
| Lecanemab | Biogen/Eisai | Approved | Aβ protofibrils | Early AD | Commercial |
| Donanemab | Eli Lilly | Approved | N-terminal Aβ | Early AD | Commercial |
| Gantenerumab | Roche | Phase III | Amyloid plaques | Early AD | Failed |
| Crenezumab | Roche | Phase III | Oligomeric Aβ | Preclinical AD | Failed |
| Solanezumab | Eli Lilly | Phase III | Mid-domain Aβ | Preclinical AD | Failed |
| Donanemab | Eli Lilly | Phase III | N-terminal Aβ | Early AD | Approved |
| ALZ-801 | Alzheon | Phase III | Amyloid aggregation | Early AD | Ongoing |
| Drug | Company | Phase | Target | Indication |
|---|---|---|---|---|
| Semorinemab | Roche/Genentech | Phase II | Tau | AD |
| Gosuranemab | Biogen | Phase II | Tau | AD |
| Tilavonemab | AbbVie | Phase II | Tau | AD |
| JNJ-63733657 | J&J | Phase I | Tau | AD |
| ABBV-8E12 | AbbVie | Phase II | Tau | FTD |
| Drug | Company | Phase | Target | Indication |
|---|---|---|---|---|
| Cinpanemab | Biogen | Phase II | α-syn | PD |
| Prasinezumab | Roche | Phase II | α-syn | PD |
| ABBV-951 | AbbVie | Phase I | α-syn | PD |
| Drug | Company | Phase | Mechanism | Indication |
|---|---|---|---|---|
| AC Immune/Roche | Bispecific | Phase I | Tau/Aβ | AD |
| Biogen/TCR | Bispecific | Phase I | Tau | AD |
AD: ████████████████████ $4.2B
PD: ████████████ $2.1B
ALS: ████████ $1.4B
FTD: ████ $620M
Other: ██ $380M
](https://clinicaltrials.gov/search?cond=neurodegeneration&intr=antibody)
van Dyck CH et al. Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023. ↩︎
Ostrowitzki S et al. Gantenerumab for Alzheimer's Disease. Nature Medicine. 2022. ↩︎
Mintun MA et al. Donanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023. ↩︎